A carregar cotações...
Previsão
Não temos dados de analistas para esta empresa.
Notícias Ir para o feed de notícias
Innocan Pharma plans listing on NYSE American by Jan. 30
Innocan Pharma expects to be listed on the NYSE American by January 30, 2026, subject to approval and compliance with exchange rules. The company is simultaneously considering, depending on market conditions and regulatory approval, a concurrent offering of securities; details will be provided in SEC and SEDAR+ filings. Common shares are expected to continue trading on the OTCQB until the close of trading on or about January 29; trading on the CSE under the ticker INNO will remain in place. Innocan reports a market capitalization of roughly $19.72 million, more cash than debt, a current ratio of 3.72, and a share price trading near its 52-week low. » Mais em de.investing.com
InnoCan Pharma reports Q3 EPS loss of CAD 0.49 and 20% revenue decline
For the quarter ended September 30, 2025, InnoCan Pharma reported an EPS loss of CAD 0.49 per share (year-ago: -CAD 0.090). Revenue fell to CAD 9.4 million from CAD 11.8 million in the year-ago quarter, a decline of 20.07%. The figures were presented at the financial conference for the quarter ended on November 26, 2025. » Mais em finanzen.net
Dados financeiros da empresa
| (EUR) | junho de 2026 | |
|---|---|---|
| Receitas | 4,48 mi | 24,57% |
| Ganho bruto | 4,07 mi | 22,52% |
| Ganho líquido | -29,03 mil | 94,20% |
| EBITDA | -429,54 mil | 427,38% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 6,41 mi |
Número de ações | 4,5 mi |
Máximo/mínimo de 52 semanas | € 12,53 - € 1,30 |
| Dividendos | Não |
Beta | -0,22 |
PER (PE Ratio) | -7,49 |
PEG (PEG Ratio) | 0,07 |
P/VC (PB Ratio) | 1,46 |
P/V (PS Ratio) | 0,30 |
Perfil da empresa
| Nome | Innocan Pharma |
| CEO | Iris Bincovich |
| Sede | Calgary,
ab Canadá |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Cuidados de saúde: prestadores e serviços |
| Colaboradores | 11 |
